Navigation Links
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Date:5/15/2013

stigational compounds in our growing oncology pipeline."

The LUX-Lung 6 Clinical Trial of Afatinib
LUX-Lung 6 (Efficacy) Abstract: #8016
Poster Discussion: Sunday, June 2, 11:30 AM-12:30 PM, poster board #5

The LUX-Lung 6 trial is the largest randomized, open-label Phase III trial conducted to date in the EGFR mutation-positive advanced (stage IIIb or IV) NSCLC patient population. The trial evaluated afatinib compared to standard chemotherapy (gemcitabine and cisplatin), as a first-line treatment in 364 Asian patients.1

The trial met its primary endpoint of PFS as assessed by independent central review; within the general study population, patients treated with afatinib (n=242) lived for a median of 11.0 months before their tumor started to grow again versus 5.6 months for patients treated with chemotherapy (n=122) (HR=0.28, p<0.0001).1 The PFS findings were consistent across EGFR mutation sub-groups.1 Secondary efficacy endpoints included objective response rate (ORR: proportion of patients with tumor size reduction of a predefined amount and for a minimum time period3) and disease control rate (DCR: proportion of patients who have achieved complete response, partial response and stable disease4). Patients treated with afatinib experienced significantly higher ORR (66.9% versus 23.0%, p<0.0001) and DCR (92.6% versus 76.2%, p<0.0001) compared to patients treated with chemotherapy.1

The most common greater than or equal to grade 3 drug-related adverse events observed in the afatinib treatment arm were rash/acne (14.6%), diarrhea (5.4%) and stomatitis/mucositis (5.4%).1 The most common greater than or equal to grade 3 drug-related adverse events observed in the gemcitabine/cisplatin treatment arm were neutropenia (17.7%), vomiting (15.9%) and leukopenia (13.3%).1 Overall, 5.9 percent of patients treated
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Jan. 4, 2012   Unigene Laboratories, Inc. (OTCBB: ... manufacture and development of peptide-based therapeutics, announced that Ashleigh ... corporate overview at the Biotech Showcase™ 2012 in San ... a.m. PT (2:30 p.m. ET).  Mr. Palmer,s presentation will include ...
... Group, an international generic pharmaceuticals company, today announced ... Food & Drug Administration to market Methylphenidate Hydrochloride ... 40mg.  Actavis has first-to-file exclusivity on the 20mg, ... has commenced.  Methylphenidate Hydrochloride Extended-Release ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity 2
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
(Date:4/22/2014)... . , Reactive ... mode of action is complex: In low concentrations they ... at high concentrations they can cause "oxidative stress", which ... signaling unfolds in single cells and organelles in real-time, ... by the teams of LMU Professor Martin Kerschensteiner and ...
Breaking Medicine News(10 mins):Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2
... than in for-profit residences, review finds , WEDNESDAY, Aug. ... care than for-profit facilities, say Canadian researchers who reviewed ... , Forty studies found that non-profit nursing homes provided ... for-profit homes delivered better care. The remaining studies had ...
... , , FRIENDSWOOD, Texas, Aug. ... develops, manages and owns faith-based senior living facilities, today announced the ... development of a new senior living facility in the Houston, Texas ... $10 million senior living facility in Katy, Texas, should be available ...
... , , , NASHVILLE, ... payment cycle management solutions, today announced the implementation of its ... Group. The Sentinel Group, a recognized leader in healthcare fraud ... 5, 2009. , , The Sentinel ...
... NANJING, China, Aug. 5 /PRNewswire-Asia/ -- ... manufacturer and supplier of branded generic and,innovative anti-cancer pharmaceuticals ... 2009 second quarter results on Monday, August 17, 2009,after ... executive,officer, Jinsheng Ren, and chief financial officer, Frank Zhigang ...
... INDIANAPOLIS, Aug. 5 In the midst of the down economy, ... worse - forcing them to make difficult sacrifices to afford medications ... On Aug. 1, 2009, Lilly USA adjusted the income ... enrollment of eligible patients with incomes at or less than 300 ...
... , HACKENSACK, N.J., Aug 5 ReGen Biologics, a ... regarding its Menaflex collagen meniscus implant that were made in a ... party unaffiliated with the company. ReGen was unaware of ... on the Internet. The statements made in the release do ...
Cached Medicine News:Health News:Not-For-Profit Nursing Homes Fare Better in Studies 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 2Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 4Health News:Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 3Health News:ReGen Biologics Clarifies Recent Press about the Menaflex Device 2
Acetate Plate Sealers 100/Box...
... Microseal 'B' seals provide an adhesive-based sealing ... The aggressive adhesive layer ensures secure sample ... and tight sealing during thermal cycling when ... lid. The perforated end-tabs can be removed ...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
Inquire...
Medicine Products: